Alkeus Pharmaceuticals, Inc., a biopharmaceutical company dedicated to preserving the sight of individuals impacted by retinal diseases, today announced that data from its clinical studies of ...

Please provide your email address to receive an email when new articles are posted on . The study met its primary endpoint, and patients who received gildeuretinol (Alkeus Pharmaceuticals) showed a ...

Ascidian Therapeutics, a biotechnology company seeking to treat human diseases by rewriting RNA, today announced it will present two oral presentations and one poster presentation at the American ...

Belite Bio (NASDAQ:BLTE) highlighted progress for its lead drug candidate tinlarebant during the 30th Deutsche Bank Depositary Receipts Virtual Investor Conference, outlining late-stage clinical devel ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. There were no serious adverse events reported in the six ...

Belite Bio (NASDAQ: BLTE) is one of the best up and coming stocks with highest upside potential. On April 21, Belite Bio ...

SEATTLE--(BUSINESS WIRE)--Kubota Vision Inc. (“Kubota Vision”), a clinical-stage ophthalmology company and wholly-owned subsidiary of Kubota Pharmaceutical Holdings Co., Ltd. (Tokyo 4596), today ...

Ocugen announces FDA alignment for Phase 2/3 trial of gene therapy OCU410ST for Stargardt disease, showing promising initial results. Ocugen, Inc. announced it has received FDA approval to proceed ...

GARDian3 trial enrollment and dosing completed (N=63) in less than nine months Topline results expected in 2Q27 with BLA to follow by mid-2027 OCU410ST represents a potential first-in-class, one-time ...

The MarketWatch News Department was not involved in the creation of this content. -- VG801 shows encouraging preliminary efficacy in the ongoing Phase 1/2 trial, with consistent functional ...

Belite Bio, Inc., a clinical-stage biopharmaceutical company focusing on treatments for degenerative retinal diseases, announced that it will present two posters at the upcoming ARVO Annual Meeting ...